Erectile Dysfunction Drugs Market - Granular Market Report And Review, 2019

Market Research Future published a Half Cooked research report on “Global  Erectile Dysfunction Drugs Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Pfizer Inc. (U.S), Bayer AG (Germany), Eli Lily & Co. (U.S), Dong–A Pharmaceutical Co. Ltd. (South Korea), Apricus Biosciences Inc.(U.S), S.K. Chemicals Co. Ltd. (South Korea), Apricus Biosciences Inc. (U.S), Cristalia Produtos Quimicos Farmaceuticos Ltd. (Brazil), Dong-A Pharmaceutical Co. Ltd., (South Korea), Meda Pharmaceuticals, Inc. (U.S),  Vivus, Inc. (U.S),  and others are some of the prominent players at the forefront of competition in the global erectile dysfunction drugs market and are profiled in MRFR Analysis. 

Global Erectile Dysfunction Drugs Market - Overview

Erectile dysfunction is the inability to attain or maintain penile erection in men, sufficient for successful sexual intercourse. It is also known as impotence. It is a common medical disorder primarily affecting men older than 40 years of age. Growing elderly population, increasing awareness and patient education, elevated inclination towards a sedentary lifestyle, and growing incidence of several genitourinary diseases are some of the factors expected to drive the growth of the global erectile dysfunction drugs market. Management of this disorder includes medical history, sexual history and psychological history of a person. There are number of drugs available for the treatment of erectile dysfunction which include both branded and generic drugs. Over 20 million men all over the world have used or are currently using Viagra to treat erectile dysfunction.

The global erectile dysfunction drugs market size is expected to grow at a CAGR of 6.5% during the forecast period 2017-2023. 

Stress and mental health concerns may worsen the problem of erectile dysfunction. Physical and psychological issues may also cause erectile dysfunction. The market of erectile dysfunction drugs is driven by the number of drugs available in the market and increasing number of men suffering from this disorder. There is also an increase in the competition among the major market players. According to a trials conducted by the American Urological Association (AUA) Consensus Panel on Erectile Dysfunction, 36% to 76% of patients on erectile dysfunction drug were able to achieve intercourse during treatment.

The market for erectile dysfunction drugs is growing rapidly and expected to continue its growth in near future. However, factors such as growing threat from counterfeit drugs, prevalence of STDs in erectile dysfunction drug users, and shrinking insurance coverage for ED treatment will hamper the growth of global erectile dysfunction market. Moreover, patent expiry of number of blockbuster drugs, availability of counterfeit drugs and increasing manufactures of generic drugs in the market may result in the decline of erectile dysfunction drugs market. Global market of erectile dysfunction drugs is expected to reach USD 2.95 billion in 2023 from USD 1.65 billion in 2016 over the forecast period 2017-2023.

Global Erectile Dysfunction Drugs Market – Regional:

Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.

The Americas account for the major share of the market owing to the presence of patient population, well-developed technology, and high healthcare expenditure. According to University of Wisconsin Hospitals and Clinics Authority, about 5 percent of men that are 40 years old have complete erectile dysfunction, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.

Europe holds the major share of the market, which is majorly contributed by Germany, the U.K., and France. According to the UK Health Centre, 50 percent of men that smoke a pack of cigarettes a day have a higher chance of developing erectile dysfunction. Furthermore, as per a study recently presented at the European Association of Urology showed that erectile dysfunction isn’t being treated very often, with only 25.4 percent of men in the being treated for the condition.

Asia Pacific is the fastest growing market owing to rapidly changing healthcare sector, and the presence of huge opportunities for the development of this market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East holds the major share of the regional market due to well-developed technology and high spending.

Global Erectile Dysfunction Drugs Market Players:

Pfizer Inc. manufactures Viagra drug for erectile dysfunction treatment. Bayer AG manufactures Levitra drugs for the treatment of erectile dysfunction. Eli Lilly and Company manufactures a drug named Cialis for erectile dysfunction.

For instance, in May 2014, Sanofi and Eli Lilly and Company announced an agreement for regulatory OTC approval of Cialis (tadalafil). Cialis is now available as OTC drug worldwide for the treatment of men with erectile dysfunction (ED).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313 

Current And Forthcoming Blood Glucose Test Strip Market Size In Terms Of Volume And Value 2020

Competitive Analysis

There are a number of players operating in this market all over the globe. Now-a-days, there is a significant increase in the number of the company offering blood glucose test strip.  Thus, companies are adopting the new strategies to minimize the competition and increase the market share. Some major companies are trying to focus on new and advanced tests & products to gain the market. Whereas, some are has used the technique of acquisition and collaboration to gain the market. Technological advancements and product development represent attractive strategies adopted by some of the leading players for the market. For instance, Bayer developed CONTOUR NEXT (CN) test strip that can used by both trained laboratory personnel and diabetic patients. This test strip uses a flavin adenine dinucleotide-glucose dehydrogenase (FAD-GDH) enzyme, a proprietary phenothiazine electron mediator and algorithm to minimize errors during the testing process.

Key players profiled in the report are Abbott, Roche Diagnostics, LifeScan, i-SENS, Bayer Diabetes Care, AgaMatrix Inc, Elektronika, Universal Biosensors, Nipro Diagnostics, TaiDoc, Apex Biotechnology Corp, B. Braun, HMD BioMedical Inc., ALL Medicus, SANNUO, Beijing Yicheng Electronics, Betachek National Diagnostics, Shanghai MicroSense, Jiangsu Yuyue, ACON Laboratories, and others.

Latest Industry Updates

Being a competitive market, a number of different manufacturer are focusing on the product launch, and acquisition for the market development. Some of the latest development in the market are-

LifeScan’s OneTouch Verio test strips are based on innovative opposing electrode technology developed by Universal Biosensors. This technology provides instant results of blood glucose levels and does not require calibration. Moreover, the results are unaffected by the presence of unrelated sugars such as maltose and galactose, which interfere with the results in a number of other blood glucose systems.

Global Blood Glucose Test Strip Market – Overview

Blood glucose test strip is a small disposable plastic strip and is an important component of blood glucose meters that monitors and controls diabetes. These strips are impregnated with glucose oxidase, which reacts with glucose present in the blood and indicate of the blood glucose level. The global blood glucose test strip market size is expected to reach USD 18.5 billion by 2020, and the market is projected to grow at a CAGR of ~ 6.2 % during the forecast period 2015-2020. The market may experience the growth due to several forces, such as government initiatives, convenience offered by self-blood glucose testing over the traditional methods, support and incentives by the governments and healthcare organizations etc. The rising diabetic population is another major driver of the market and one of the major concerns for the government across the globe. According to International Diabetic Federation, about 415 million people had diabetes in 2015, and this number is estimated to reach 642 million by 2040.

Poor reimbursement policy for the test strips may hinder the growth of the market over the forecast period. In March 2013, Medicare announced reimbursement cuts for diabetes testing supplies (DTS) up to 72%, which although reduces the healthcare expenditure; but also drastically reduces the number of vendors from which diabetic patients can obtain glucose-testing supplies. This may reduce the market for blood glucose test strip.

During last few decades, there is a significant increase in the number of patients suffering from diabetes, thus, a number of manufacturers are focusing on the introduction of the new and advanced type of devices which are more easy to handle and more cost-effective than the present available devices.

Regional Analysis

Regionally, the global blood glucose test strip market is segmented into: Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas holds a significant market share of the global market owing to extensive use of information technology and high expenditure on the health care. Additionally, the fastest uptake of new technology and the presence & concentration of medical device manufacturers in the US regions drive the blood glucose test strip market. Europe is the second largest market in the globe due to a high healthcare expenditure, which is led by Germany and France. Asia Pacific region is expected to grow rapidly; China and India are likely to lead the market due to unmet needs during the forecasted period. Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic & political conditions and poor healthcare development.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/global-blood-glucose-test-strip-market-976 

Clinical Nutrition Market In Depth Study And Analysis Published, 2019

Clinical Nutrition Market-Overview

Clinical nutrition mainly focuses on the development of nutritional products especially for the patients suffering from chronic diseases such as diabetes, chronic obstructive pulmonary disease, gastrointestinal disorders, cancer, immune system disorders, liver and kidney diseases, and many more. Rising prevalence of chronic diseases, extensive demand for clinical nutrition therapy, and growing awareness about the use of nutritional products drive the growth of the market. Additionally, the prevalence of lifestyle diseases such as obesity, and addiction to smoking and alcohol also stimulate the market growth. The market is expected to show flourishing growth in developing regions of Asia Pacific owing to a rising economic burden of chronic diseases and increasing demand for nutritional supplements. Clinical nutrition is now becoming an important field of interest, due to increase important of nutrition to be provided to the patient during his/her stay at the hospital as well as at home. Quality of products offered by the company determines the quality goals and efficiency that can be achieved so as to attract more and more customers, and increase in the sale of nutritional products. The products are needed to be manufactured through quality assurance and quality control market, thus sustaining the position in the market. Therefore, the company should strive to develop qualitative products to attract more and more customers, and enhance its growth.

Key players in the Clinical Nutrition Market:

Abbott (U.S.), AYMES Nutrition International Ltd. (U.K), NeoMed (U.S.), Baxter International (U.S.), Danone (France), B. Braun Melsungen AG (Germany), Mead Johnson & Company, LLC. (U.S.), Nestlé Health Science (Switzerland), Nutricia Advanced  Clinical nutrition (Netherland), Primus Pharmaceuticals (U.S.), Inc., Solace Nutrition (U.K) and others. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population.

Key Developments:

Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players. This help the companies to reach untapped markets in developing nations of the worlds, thus reducing the supply demand gap. The companies develop number of nutritional products for patients, addressing their according to the disease condition. 

Danone:

• Danone is a French multinational food-products company in France. The company introduced, SYNEO which is the first and only hypoallergenic formula containing prebiotics as well as probiotics for the infants suffering from cow’s milk allergy, multiple food allergies, and related gastrointestinal conditions.

Nestlé Health Science:

• In October, 2015, Nestlé Health Science has announced its collaboration with GE Healthcare to improve nutrition monitoring for critically-ill patients. RESOURCE, BOOST, PRONOURISH are some of the major product of the company.
• Nestlé Health Science has acquired Vitaflo headquartered in UK to establish a foothold in the fast-growing market for uniquely formulated products. It has 2nd largest market in US and 1st in Canada.
• In 2015, Nestlé Health Science acquired Phagenesis, a UK-based company developing Phagenyx, an innovative pharyngeal electrical stimulation device to treat dysphagia.
• In July, 2015: Nestlé Health Science signed with Seres Therapeutics’ novel class of microbiome therapeutics (Ecobiotics) an exclusive agreement outside the United States and Canada for in the fields of Clostridium difficile infections and Inflammatory Bowel Disease (IBD).

Abbott Nutrition:

• Abbott manufactures, and sales enormous clinical nutrition products for adult, infant & new mother, infant & new mother, sports & active living, and therapeutic use. The company supplies these nutrition products under various brand names such as Similac, PediaSure, Pedialyte, Ensure, ZonePerfec, EAS, and Glucerna. The company focuses on healthy diabetes, malnutrition, and heart health.
• June, 2016: Abbott launched new EAS Protein Shakes, Powders and Bars especially for the Athletes with an aim of fuelling their Lifestyles, improving strength, and enhance their performance. The company strives to provide clinically proven nutrition for health-conscious individuals and athletes at every stage of their development, from beginner to professional.
• April, 2016: Abbott Launched EAS Myoplex Sports Nutrition Line for designed for performance. The product form new line are Myoplex Pre-Workout, Myoplex BCAA + Electrolytes, Myoplex Protein Blend, and Myoplex Micellar Casein.

Research in Clinical Nutrition by Key Players:

Abbott:  A research carried out by University of Illinois and Abbott at the Centre for Nutrition, Learning and Memory discovered that children with higher lutein levels in the eye tend to do better on tests of cognition and academic achievement. This help Abbot to understand the role of nutrition on childhood cognition, which will further help the company to develop product providing maximum benefits children enhancing their cognitive abilities.

Therefore, the market is driven by availability of numerous nutritional products, strategic approaches, and geographical expansion by key players. 

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/global-clinical-nutrition-market-829 

Latest Study Offers Detailed Insights On Healthcare Revenue Cycle Management Market 2019

Market Scenario
Market Research Future Published a Cooked Research Report on Healthcare Revenue Cycle Management Market Research Report – Forecast to 2027.

Healthcare revenue cycle management (RCM) is a software that manages and simplifies all administrative and clinical functions including claims process, payment, revenue generation, patient registration, medical documentation, insurance verification, and accounts receivable & collections. Healthcare revenue cycle management software has gained profound importance in the healthcare sector in recent years. The global healthcare revenue cycle management market is anticipated to register a CAGR of 12.2% over the forecast period of 2017-2027, asserts Market Research Future (MRFR) in a detailed research report.

Towering costs of surgeries and overall healthcare has prompted hospitals to resort to technologies to reduce burden. Simplification of financial transactions is a key growth motivator which has spurred the adoption of RCM software among hospitals. In addition, expansion of healthcare budget and increase in a number of hospital chains and healthcare services across the globe fares well for the market. RCM software allows healthcare institutions to not only increase accuracy and timeliness but also helps them adhere to continuously evolving regulatory norms. RCM software can be applied to every aspect of the revenue cycle and is gaining traction among healthcare institutions.

On the downside, the growth of the global healthcare revenue cycle management market might be deterred by a dearth of trained healthcare professionals to operate the software. The global healthcare revenue cycle management market is anticipated to reach USD 1,75,163.5 Mn by the end of 2027.

Key Players for Global Healthcare Revenue Cycle Management (RCM) Market

• Epic Systems Corporation (US),
• McKesson Corporation (US),
• Cerner Corporation (US),
• General Electric Company (US),
• Allscripts (US),
• Quest Diagnostic (US),
• Siemens Healthcare (Germany),
• AdvantEdge Healthcare Solutions (US),
• CareCloud (US),
• Acelerartech (US),
• 3M (US).

Intended Audience

• Healthcare Revenue Cycle Management (RCM) Products Manufacturers
• Healthcare Revenue Cycle Management (RCM) Products Providers
• Medical Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Segmentation                                                                                                                                 
The global healthcare RCM market is segmented on the basis of deployment, component, product types, and end users.

On the basis of deployment, the market is segmented into on-premises, and cloud-based.

On the basis of component, the market is categorized into services, and software.

On the basis of product types, the market is divided into integrated software, and standalone software.

On the basis of end users, the market is shared into hospitals, ambulatory services and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-revenue-cycle-management-market-878 

Americas Blood Glucose Test Strip Packaging Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

Market Synopsis of Americas Blood Glucose Test Strip Packaging Market:

An expert on premium research reports, Market Research Future has added a report titled "Americas Blood Glucose Test Strip Packaging Market Research Report – Forecast to 2021" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.

Americas Blood Glucose Test Strip Packaging Market– Forecast to 2021 The report firstly introduced Americas Blood Glucose Test Strip Packaging Market including classification, application and industry chain overview; Then we deeply analyzed Americas growth forecast indicators by the as well as the regional market conditions that including the product price, profit, utilization, supply, demand and industry growth rate etc.

In the end, the report introduced medical suction device market SWOT analysis, PEST analysis, market share analysis and competitive landscape, company profiles by analyzing the major players. It is a depth research study on Americas Blood Glucose Test Strip Packaging Market trends. We are thankful for the support and assistance from Americas Blood Glucose Test Strip Packaging Market chain related technical experts and marketing experts during Research Team survey and interviews.

Browse More Report @  https://www.marketresearchfuture.com/reports/americas-blood-glucose-test-strip-packaging-industry-576 

Detailed Table Of Contents

1 Introduction

1.1 Definition

1.2 Scope Of The Study

1.2.1 Research Objectives

1.2.2 Assumptions & Limitations

1.3 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

2.4 Forecast Model

3 Report Excerpt

4 Forecast Indicators

4.1 Introduction

4.2 Growth Drivers

4.3 Growth Barriers

4.4 Growth Opportunities

4.5 Macroecnomical Indicators

5 Market Analysis

6 Americas Blood Glucose Test Strip Market

6.1 Introduction

6.2 By Volume

6.3 By Value

7 Americas Blood Glucose Test Strip Packaging Market, By Product Type

7.1 Introduction

7.2 Plastic Vials

7.2.1 Plastic Vials With Loose Desiccant

7.2.2 Plastic Vials With Injected Desiccant

7.3 7.2.3 Plastic Vials With Other Desiccant

7.2.4 Plastic Vials Without Desiccant

7.3 Aluminium Foils By Value

7.4 Others

…TOC Continued!

Enema Based Products Market To Observe Strong Development By 2019

Market Synopsis of the Global Enema Based Products Market

The global enema based products market is expected to show sharp growth over the forecast period. Rising Enema Based Products Market demand and prevalence of gastrointestinal disorders such as constipation across the globe, availability of various types of enema administration kits such as cleansing and carminative enema and overall demand for enema administration products drivers the market growth.

Enema based products are used to remove waste for the rectum and can be used at home as a remedial measure for constipation and other gastrointestinal disorders. Constipation is a major gastrointestinal condition, found to be prevalent across the globe. Other condition that may require enema administration are obesity, diabetes, and cancer.

Risk involved in the use of enema based product is irritation in the rectum and embolism, in case of incorrect use of enema administration

According to the latest 2016 data from the World Health Organization, an estimated 422 million adults were living with diabetes mellitus across the globe.

The global enema based products market is expected to grow at a CAGR of 10.2% during the forecast period.

Key Players

Some of the key players in this market are Baxter International, Inc. (U.S), MacoPharma (U.K),  Hollister Incorporated  (U.S), Coloplast Group (Germany), Medline Industries, Inc. (U.S), and B Braun Melsungen AG (Germany).

Segments

The global enema based products market is segmented on the basis of administration type, indication, preparation, and end users.

On the basis of administration type, market is segmented into cleansing enema, carminative enema, retention enema, return-flow enema, and others. Cleansing enema is further segmented into large volume enema, small volume enema, and prepackaged disposable enema. Retention enema is further segmented into oil enema, sedative enema, nutrient enema, anesthetic enema, medicinal enema, and others.

On the basis of indication, the market is market is segmented into constipation, diarrhea, obesity, cancer and others.

On the basis of preparation, the market is divided into sodium phosphate enemas, coffee enemas, barium enemas, water-soluble contrast enemas and others.  Barium enemas is further segmented into single-column barium enema and double-contrast barium enema.

On the basis of end user, the market is divided into hospitals or clinics, home, and others. 

Regional Analysis

The global enema based products market size by regional basis is segmented into regions namely Americas, Europe, Asia Pacific and the Middle East & Africa. America is the largest market for enema based products owing to increasing use of enema based products at home, and rising demand for enema kits by healthcare providers. According to the Canadian Journal of Gastroenterology, constipation is a common problem among the people in the North American region. One of the study stated that the 20% of the North American population suffer from constipation.

Europe is the second largest market owing rise in the number of enema administration procedures in the hospitals. Rising prevalence of constipation, diarrhea, and obesity also contributes to the progress of the market. Prevalence of diabetes is also found to be increasing in the Europe. According to the World Health Organization, nearly 60 million people with diabetes in the European Region and the prevalence is higher among people aging 25 years and above.

In Asia Pacific, the prevalence of chronic diseases such as diabetes and obesity is found to be increasing. Diabetes is one of the major problem in China and India. India has world’s second largest population of diabetic patients, around 69.2 million in 2015 and that are expected to increase to 123.5 million by 2040. The number of undiagnosed diabetes is higher in India which was around 36 million in 2015.

The Middle East & Africa also shows a steady rise in the market owing to lack of physical exercise, increasing problem of constipation and availability of enema based products in the market.

Browse More Report Details @ https://www.marketresearchfuture.com/reports/enema-based-products-market-4370 

Cardiac Valve Market Pipeline Review, 2019- Identify Key Business Opportunities

Market scenario

An expert on premium research reports, Market Research Future asserts that, Global Cardiac Valve Market is expected to grow at a CAGR of 11.5% during the forecasted period.

Cardiac valve or heart valve allows blood to flow in only one direction through the heart. Human heart consists of four valves. These valves open and closes compulsory on differential blood pressure on each side.

Furthermore, valve replacement remains the most widely used technique but the proportion of valve repair procedures is increasing in experienced treatment centres. Moreover, increasing development in medical technology and its wide range of application used in the treatment of various cardiac diseases will fuel the growth of the market. However, high cost of the treatment likely to restrain the growth of the market over the assessment period. The global cardiac valve market is expected to grow at a CAGR of 11.5% during the forecast period.

Key players

Medtronic (U.S.), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK HealthCare (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil) are some of the prominent players at the forefront of competition in the Global Cardiac Valve Market and are profiled in MRFR Analysis. 

Segmentation

The global cardiac valve market is segmented on the basis of types, by diseases, by treatment, and by end users.

On the basis of treatments, it is segmented into valve replacement, valve repair, and others.

On the basis of types, the market is segmented into trans-catheter heart valve, tissue heart valve, mechanical heart valve, and others.

On the basis of disease, the market is segmented into aortic valve replacement, heart valve disease, mitral valve stenosis, and others.

On the basis of end users the market is segmented into cardiac research institute, hospital & clinics, and others.

Regional analysis

The Americas mainly include North America and South America of which North America dominates the market owing to the presence of huge number of patient with cardiac diseases, increasing geriatric population, and increasing healthcare expenditure.  

In Asia Pacific, increasing government support for research & development in healthcare domain, growing number of cardiovascular diseases drive the growth of the market in this region.

Europe is the second highest revenue generating region in the cardiac valve market. Europe is mainly consist of Eastern Europe and Western Europe. More developed countries of Western Europe such as Germany, France, and the UK are holding the major market share, whereas the East European countries are also growing at a significant rate. Moreover, owing to developing healthcare infrastructure and increasing healthcare expenditure will boost the market growth in this region.

The Middle East & Africa is expected to show a least market share due to less availability of medical facilities, and less development in healthcare domain

Browse More Report Details @ https://www.marketresearchfuture.com/reports/cardiac-valve-market-560